Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. (vol 369, pg 559, 2007)

被引：0
|
作者：
Coombes, R. C.
Kilburn, L. S.
Snowdon, C. F.
机构：
来源：
LANCET | 2007年 / 369卷 / 9565期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：906 / 906
页数：1
相关论文
共 41 条
  • [21] Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial (vol 119, pg 1908, 2013)
    Burris, H. A.
    Lebrun, F.
    Rugo, J. S.
    CANCER, 2019, 125 (08) : 1387 - 1388
  • [22] Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study
    Schochter, Fabienne
    Rack, Brigitte
    Tzschaschel, Marie
    Polasik, Arkadius
    Andergassen, Ulrich
    Trapp, Elisabeth
    Alunni-Fabbroni, Marianna
    Schneeweiss, Andreas
    Müller, Volkmar
    Pantel, Klaus
    Gade, Joerg
    Lorenz, Ralf
    Rezai, Mahdi
    Tesch, Hans
    Soeling, Ulrike
    Fehm, Tanja
    Mahner, Sven
    Schindlbeck, Christian
    Lichtenegger, Werner
    Beckmann, Matthias W.
    Fasching, Peter A.
    Janni, Wolfgang
    Friedl, Thomas W. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (03) : 93 - 98
  • [23] Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial (vol 381, pg 805, 2013)
    Davies, C.
    Pan, H.
    Godwin, J.
    LANCET, 2017, 389 (10082): : 1884 - 1884
  • [24] Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial (vol 381, pg 805, 2013)
    Davies, Christina
    LANCET, 2013, 381 (9869): : 804 - 804
  • [25] First results from the multicenter phase III DATA study comparing 3 versus 6 years of anastrozole after 2-3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer
    Tjan-Heijnen, V. C.
    Van Hellemond, I. E.
    Peer, P. G.
    Swinkels, A. C.
    Smorenburg, C. H.
    Van der Sangen, M.
    Kroep, J. R.
    De Graaf, H.
    Honkoop, A. H.
    Erdkamp, F.
    Van den Berkmortel, F. W.
    Kitzen, J. J.
    De Boer, M.
    De Roos, W. K.
    Linn, S. C.
    Imholz, A. L.
    Seynaeve, C.
    CANCER RESEARCH, 2017, 77
  • [26] A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer
    Eiichi Shiba
    Hiroko Yamashita
    Junichi Kurebayashi
    Shinzaburo Noguchi
    Hirotaka Iwase
    Yasuo Ohashi
    Kiyofumi Sasai
    Tsukasa Fujimoto
    Breast Cancer, 2016, 23 : 499 - 509
  • [27] A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer
    Shiba, Eiichi
    Yamashita, Hiroko
    Kurebayashi, Junichi
    Noguchi, Shinzaburo
    Iwase, Hirotaka
    Ohashi, Yasuo
    Sasai, Kiyofumi
    Fujimoto, Tsukasa
    BREAST CANCER, 2016, 23 (03) : 499 - 509
  • [28] Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial (vol 2, pg 369, 2014)
    Barnett, A. H.
    Mithal, A.
    Manassie, J.
    LANCET DIABETES & ENDOCRINOLOGY, 2015, 3 (03): : E2 - E2
  • [29] A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer
    Junichi Kurebayashi
    Eiichi Shiba
    Tatsuya Toyama
    Hiroshi Matsumoto
    Minoru Okazaki
    Tadashi Nomizu
    Tohru Ohtake
    Takaaki Fujii
    Yasuo Ohashi
    Breast Cancer, 2021, 28 : 684 - 697
  • [30] A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer
    Kurebayashi, Junichi
    Shiba, Eiichi
    Toyama, Tatsuya
    Matsumoto, Hiroshi
    Okazaki, Minoru
    Nomizu, Tadashi
    Ohtake, Tohru
    Fujii, Takaaki
    Ohashi, Yasuo
    BREAST CANCER, 2021, 28 (03) : 684 - 697
12345